|
|
Expression of STAT6 and NF-κB p65 in the
colon mucosa of patients with ulcerative colitis |
Rui ZHU MD,Heng FAN MD,Lin SHEN MD,Jianguo LIU BD,Jia ZHAO MM, |
Department of Traditional
Chinese Medicine, Union Hospital, Tongji Medical College, Huazhong
University of Science and Technology, Wuhan 430022, China; |
|
|
Abstract The expression of signal transducer and activator of transcription 6 (STAT6) and nuclear factor-κB (NF-κB) in the colonic mucosa of patients with ulcerative colitis (UC) was examined. Real-time polymerase chain reaction and immunohistochemistry were used to detect the expression of STAT6 and NF-κB p65 at both mRNA and protein levels in the colonic mucosa of patients with UC and healthy volunteers. The results showed that the expression levels of STAT6 and NFκB p65 in the colonic mucosa of patients with UC were significantly higher than in normal controls at both mRNA and protein levels. These data suggest that STAT6 and NFκB p65 perhaps play an important role in the pathogenesis of UC and underscore the potential value of anti-UC strategies in the clinical management of this disease.
|
Keywords
ulcerative colitis
signal transducer and activator of transcription 6 (STAT6)
nuclear factor-κB p65 (NF-κB p65)
|
Issue Date: 05 December 2009
|
|
|
Lampinen M, Backman M, Winqvist O, Rorsman F, Rönnblom A, Sangfelt P, Carlson M. Differentregulation of eosinophil activity in Crohn’s disease comparedwith ulcerative colitis. J Leukoc Biol, 2008, 84(6): 1392―1399
doi: 10.1189/jlb.0807513
|
|
Lakatos L, Lakatos P L. Is the incidence and prevalenceof inflammatory bowel diseases increasing in Eastern Europe? Postgrad Med J, 2006, 82(967): 332―337
doi: 10.1136/pgmj.2005.042416
|
|
Shteingart S, Rapoport M, Grodzovski I, Sabag O, Lichtenstein M, Eavri R, Lorberboum-Galski H. Therapeuticpotency of IL2―caspase 3 targeted treatment in a murine experimentalmodel of inflammatory bowel disease. Gut, 2009, 58(6): 790―798
doi: 10.1136/gut.2008.153981
|
|
Trinatafillidis J K, Nasioulas G, Kosmidis P A. Colorectal cancer and inflammatory bowel disease: Epidemiology,risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res, 2009, 29(7): 2727―2737
|
|
Knight P, Campbell B J, Rhodes J M. Host-bacteria interaction in inflammatory bowel disease. Br Med Bull, 2008, 88(1): 95―113
doi: 10.1093/bmb/ldn038
|
|
Atreya I, Atreya R, Neurath M F. NF-kappaB in inflammatory bowel disease. J Intern Med, 2008, 263(6): 591―596
doi: 10.1111/j.1365-2796.2008.01953.x
|
|
Han W, Joo M, Everhart M B, Christman J W, Yull F E, Blackwell T S. Myeloid cells control termination of lung inflammationthrough the NF-kappaB pathway. Am J PhysiolLung Cell Mol Physiol, 2009, 296(3): 320―327
doi: 10.1152/ajplung.90485.2008
|
|
Cheng D S, Han W, Chen S M, Sherrill T P, Chont M, Park G Y, Sheller J R, Polosukhin V V, Christman J W, Yull F E, Blackwell T S. Airway epithelium controlslung inflammation and injury through the NF-kappaB Pathway. J Immunol, 2007, 178(10): 6504―6513
|
|
Alcamo E, Mizgerd J P, Horwitz B H, Bronson R, Beg A A, Scott M, Doerschuk C M, Hynes R O, Baltimore D. Targeted mutation of TNF receptor I rescues the RelA-deficientmouse and reveals a critical role for NF-κB in leukocyte recruitment. J Immunol, 2001, 167(3): 1592―1600
|
|
Wright J G, Christman J W. The role of nuclear factorkappa B in the pathogenesis of pulmonary diseases: implications fortherapy. Am J Respir Med, 2003, 2(3): 211―219
|
|
Lee H S, Moon C, Lee H W, Park E M, Cho M S, Kang J L. Src tyrosine kinases mediate activations of NF-κb and integrinsignal during lipopolysaccharide-induced acute lung injury. J Immunol, 2007, 179(10): 7001―7011
|
|
Sen P, Wallet M A, Yi Z, Huang Y, Henderson M, Mathews C E, Earp H S, Matsushima G, Baldwin A S Jr, Tisch R M. Apoptoticcells induce Mer tyrosine kinase-dependent blockade of NF-kappaB activationin dendritic cells. Blood, 2007, 109(2): 653―660
doi: 10.1182/blood-2006-04-017368
|
|
Hayden M S, Ghosh S. Shared principles in NF-kappaBsignaling. Cell, 2008, 132(3): 344―362
doi: 10.1016/j.cell.2008.01.020
|
|
Kato T Jr, Delhase M, Hoffmann A, Karin M. CK2 Is a C-TerminalIkappaB Kinase Responsible for NF-kappaB Activation during the UVResponse. Mol Cell, 2003, 12(4): 829―839
doi: 10.1016/S1097-2765(03)00358-7
|
|
Tergaonkar V, Bottero V, Ikawa M, Li Q, Verma I M. IkappaB kinase-independent IkappaBalphadegradation pathway: functional NF-kappaB activity and implicationsfor cancer therapy. Mol Cell Biol, 2003, 23(22): 8070―8083
doi: 10.1128/MCB.23.22.8070-8083.2003
|
|
Baldwin A S Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol, 1996, 14: 649―683
doi: 10.1146/annurev.immunol.14.1.649
|
|
Jones M R, Simms B T, Lupa M M, Kogan M S, Mizgerd J P. Lung NF-kappaB activationand neutrophil recruitment require IL-1 and TNF receptor signalingduring pneumococcal pneumonia. J Immunol, 2005, 175(11): 7530―7535
|
|
Sweeney C, Li L, Shanmugam R, Bhat-Nakshatri P, Jayaprakasan V, Baldridge L A, Gardner T, Smith M, Nakshatri H, Cheng L. Nuclear factor-kappaBis constitutively activated in prostate cancer in vitro and is overexpressedin prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res, 2004, 10(16): 5501―5507
doi: 10.1158/1078-0432.CCR-0571-03
|
|
Karin M, Cao Y, Greten F R, Li Z W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer, 2002, 2(4): 301―310
doi: 10.1038/nrc780
|
|
Caamaño J, Hunter C A. NF-kappaB family of transcriptionfactors: central regulators of innate and adaptive immune functions. Clin Microbiol Rev, 2002, 15(3): 414―429
doi: 10.1128/CMR.15.3.414-429.2002
|
|
Li Q, Verma I M. NF-kappaB regulation in theimmune system. Nat Rev Immunol, 2002, 2(10): 725―734
doi: 10.1038/nri910
|
|
Senftleben U, Li Z W, Baud V, Karin M. IKKbeta isessential for protecting T cells from TNFalpha-induced apoptosis. Immunity, 2001, 14(3): 217―230
doi: 10.1016/S1074-7613(01)00104-2
|
|
Mora A, Youn J, Keegan A, Boothby M. NF-kappaB/Rel participation in the lymphokine-dependent proliferation of Tlymphoid cells. J Immunol, 2001, 166(4): 2218―2227
|
|
Hettmann T, DiDonato J, Karin M, Leiden J M. An essential role for nuclear factor kappaB in promoting doublepositive thymocyte apoptosis. J Exp Med, 1999, 189(1): 145―158
doi: 10.1084/jem.189.1.145
|
|
Tak P P, Firestein G S. NF-kappaB: a key role ininflammatory diseases. J Clin Invest, 2001, 107(1): 7―11
doi: 10.1172/JCI11830
|
|
Perkins N D. The Rel/NF-kappaB family: friend and foe. Trends Biochem Sci, 2000, 25(9): 434―440
doi: 10.1016/S0968-0004(00)01617-0
|
|
Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res, 2006, 4(4): 221―233
doi: 10.1158/1541-7786.MCR-05-0261
|
|
Neurath M F, Fuss I, Schürmann G, Pettersson S, Arnold K, Müller-Lobeck H, Strober W, Herfarth C, Büschenfelde K H. Cytokine gene transcription by NF-kappaB family members in patients with inflammatory bowel disease. Ann N Y Acad Sci, 1998, 859: 149―159
doi: 10.1111/j.1749-6632.1998.tb11119.x
|
|
Li Z, Zhang de K, Yi W Q, Ouyang Q, Chen Y Q, Gan H T. NF-kappaB p65 antisense oligonucleotides may serve asa novel molecular approach for the treatment of patients with ulcerativecolitis. Arch Med Res, 2008, 39(8): 729―734
doi: 10.1016/j.arcmed.2008.08.001
|
|
Yang J, Stark G R. Roles of unphosphorylatedSTATs in signaling. Cell Res, 2008, 18(4): 443―451
doi: 10.1038/cr.2008.41
|
|
Darnell J E Jr. STATs and gene regulation. Science, 1997, 277(5332): 1630―1635
doi: 10.1126/science.277.5332.1630
|
|
Mudter J, Weigmann B, Bartsch B, Kiesslich R, Strand D, Galle P R, Lehr H A, Schmidt J, Neurath M F. Activation pattern of signal transducers and activators of transcription(STAT) factors in inflammatory bowel diseases. Am J Gastroenterol, 2005, 100(1): 64―72
doi: 10.1111/j.1572-0241.2005.40615.x
|
|
Hebenstreit D, Wirnsberger G, Horejs-Hoeck J, Duschl A. Signalingmechanisms, interaction partners, and target genes of STAT6. Cytokine Growth Factor Rev, 2006, 17(3): 173―188
doi: 10.1016/j.cytogfr.2006.01.004
|
|
Schindler C, Levy D E, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem, 2007, 282(28): 20059―20063
doi: 10.1074/jbc.R700016200
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|